Welcome to our dedicated page for Biocryst Pharmaceuticals SEC filings (Ticker: BCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioCryst Pharmaceuticals, Inc. SEC filings document the company's commercial rare-disease business, including ORLADEYO® results, revenue guidance, pricing disclosures, and financial results furnished on Form 8-K. The filings also describe pipeline and business-development matters involving HAE programs, including navenibart licensing and the completed acquisition of Astria Therapeutics as a BioCryst subsidiary.
BioCryst's filings further cover financing and capital-structure matters, including term-loan arrangements, as well as proxy disclosures on board elections, executive compensation, equity awards, committee structure, and shareholder voting matters. Material-event reports and proxy statements provide the formal record for governance changes, strategic transactions, and Regulation FD disclosures.
BioCryst Pharmaceuticals, Inc. filed a Form 8-K reporting the consummation of a Transaction and furnishing a set of related agreements dated October 1, 2025. The filing lists six exhibits between the company and BioCryst Ireland: an Amended and Restated IP Licence Agreement, a Supply Agreement, a Global Brand and Support Agreement, a Transition Services Agreement, a Trademark License Agreement, and a Press Release regarding the Transaction. The filing states that schedules and exhibits to those agreements were omitted from the public filing under Item 601(a)(5) of Regulation S-K and are available to the SEC on request.
Deerfield-affiliated entities and individual James E. Flynn report a 5.80% beneficial ownership stake in BioCryst Pharmaceuticals common stock, representing 12,169,000 shares. The filing states that all reporting persons have no sole voting or dispositive power and instead hold shared voting and dispositive power over 12,169,000 shares. The reporting group consists of Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P. and James E. Flynn, organized in Delaware (entities) and the United States (Flynn). The filing includes a joint filing agreement, an Item 8 statement and a previously filed power of attorney exhibit. Signatures are dated 09/19/2025.
Deerfield-affiliated entities and individual James E. Flynn report a 5.80% beneficial ownership stake in BioCryst Pharmaceuticals common stock, representing 12,169,000 shares. The filing states that all reporting persons have no sole voting or dispositive power and instead hold shared voting and dispositive power over 12,169,000 shares. The reporting group consists of Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P. and James E. Flynn, organized in Delaware (entities) and the United States (Flynn). The filing includes a joint filing agreement, an Item 8 statement and a previously filed power of attorney exhibit. Signatures are dated 09/19/2025.
Amy E. McKee, a director of BioCryst Pharmaceuticals, acquired 676 shares of the company's common stock on 08/29/2025 at a price of $8.31 per share. The shares were issued in lieu of 50% of her quarterly cash board retainer of $11,250. After the transaction, Ms. McKee beneficially owns 41,007 shares, held directly. The Form 4 was signed by Alane P. Barnes by power of attorney on 09/03/2025. This filing reports a routine director compensation conversion into equity and does not disclose other changes to ownership or derivative positions.
Frank Steven, a director of BioCryst Pharmaceuticals, acquired 1,353 shares of the company's common stock on 08/29/2025 at a price of $8.31 per share, bringing his total beneficial ownership to 16,052 shares. The shares were issued in lieu of a quarterly cash board retainer equal to $11,250, representing an election to receive equity rather than cash compensation.
This disclosure is a routine Section 16 filing reporting a director compensation-related share issuance; it reflects non-derivative, direct ownership and does not indicate any sale or derivative transactions.
BioCryst Pharmaceuticals director Vincent Milano reported an equity-based compensation transaction: on 08/29/2025 he was issued 676 shares of Common Stock at an effective price of $8.31 per share, increasing his direct beneficial ownership to 90,436 shares. The filing explains the shares were issued in lieu of 50% of the quarterly cash board retainer of $11,250, indicating part of the director's compensation was taken in stock rather than cash. The Form 4 was signed by power of attorney on 09/03/2025.
Insider trades by director Theresa Heggie at BioCryst Pharmaceuticals (BCRX): the filing shows automatic option grants and a sale on 08/13/2025. She received two automatic option grants totaling 70,000 options (30,000 at $2.91; 40,000 at $5.41) exercisable in 2020 and 2021 with 2029 and 2030 expirations. On the same date she sold 70,000 common shares at a weighted average price of $8.5124, leaving her with 65,352 shares beneficially owned.
BioCryst Pharmaceuticals (BCRX) Form 144 notifies a proposed sale of 70,000 common shares through Fidelity Brokerage Services with an aggregate market value of $595,870.74. The shares are scheduled for sale on 08/13/2025 on NASDAQ and come from a reported total outstanding share count of 209,920,430.
The filing shows the shares derive from stock options: 30,000 from an option granted 05/29/2019 and 40,000 from an option granted 05/12/2020, with the consideration listed as cash. The filer reports Nothing to Report for sales in the past three months and includes the standard representation that no undisclosed material adverse information is known to the seller.
BioCryst Pharmaceuticals, Inc. has registered 11,000,000 shares of common stock for issuance under its Stock Incentive Plan, which was amended and restated on April 21, 2025 and approved by stockholders on June 12, 2025. The Registration Statement incorporates by reference the companys Annual Report for the year ended December 31, 2024 and Quarterly Reports filed for the quarters ended March 31, 2025 and June 30, 2025, as well as a series of Current Reports filed between February and August 2025.
The filing describes the companys indemnification framework under Delaware law, noting statutory protections under Section 145 and Section 102(b)(7), the Certificate of Incorporation and Bylaws indemnification provisions, and existing directors and officers liability insurance. The filing also states that indemnification for Securities Act liabilities may be deemed unenforceable under SEC precedent. Exhibits include counsels opinion, auditor consent, the amended Stock Incentive Plan (incorporated by reference), a power of attorney, and the fee table.
BioCryst Pharmaceuticals announced that Dr. Helen Thackray will resign as Chief Research and Development Officer effective September 1, 2025. She said she will pursue new opportunities and cited no disagreement with the Board. The Company and Dr. Thackray entered a Separation Agreement providing one year of continued base salary, payment of her 2025 annual incentive plan bonus based on actual performance plus payment of her target 2025 bonus, up to 12 months of company-paid group health continuation, up to six months of outplacement services, and accelerated vesting of equity awards scheduled to vest in 2026. The Compensation Committee also approved a Consulting Agreement through December 31, 2025 under which she will provide transition services for a $12,500 monthly fee, with continued vesting of equity awards during the consulting period and six-month post-consulting option exercisability. These arrangements are intended to support an orderly transition while creating near-term compensation and equity vesting obligations.
BioCryst Pharmaceuticals, Inc. (BCRX) — 10-Q for quarter ended June 30, 2025. Key operational and financial metrics from the filing:
- Revenues: $163,353 thousand (Q2 2025) vs $109,332 thousand (Q2 2024); six months $308,887 thousand vs $202,093 thousand.
- Profitability: Net income $5,085 thousand for Q2 2025 vs a net loss in Q2 2024; six months net income $5,117 thousand vs loss $48,053 thousand.
- Liquidity & balance sheet: Cash and cash equivalents $88,033 thousand; short-term investments $172,005 thousand; total assets $457,188 thousand; stockholders' deficit $(421,594) thousand (improved vs Dec 31, 2024).
- Financing & obligations: Secured term loan $242,794 thousand; royalty financing obligations non-current $447,842 thousand; Pharmakon term loan principal repaid $69,508 thousand year-to-date.
- Other material item: On June 27, 2025 the company entered a definitive agreement to sell BioCryst Ireland (European ORLADEYO business) and has classified assets and liabilities held for sale.
Management states available resources at June 30, 2025 are sufficient to fund operations for at least the next 12 months.